Novo Nordisk Partners with Anthropic to Accelerate AI Drug Discovery Using Claude Science
8 Sources
[1]
Novo Nordisk partners with Anthropic to speed up drug discovery
"Joining forces with Anthropic will supercharge our R&D organisation and help us on our mission to bring new, transformative health solutions to people living with chronic diseases," Novo Nordisk president and CEO Mike Doustdar said in a statement. "AI can help us increase productivity in R&D and
[2]
Novo to use Anthropic's Claude to advance AI drug discovery
The deal underscores a broader push by drugmakers to integrate AI across research and development to boost new drug discovery. Novo, previously Novo Nordisk, the Danish pharmaceutical company behind Ozempic, has partnered with Anthropic to accelerate the development of new medicines using
[3]
Novo Nordisk Cut Patient Documentation From Months to Minutes. Now It Wants Claude to Speed Drug Research
Novo Nordisk is teaming up with Anthropic to use artificial intelligence to accelerate the discovery and development of new medicines, the companies announced Wednesday. The Danish pharmaceutical company, best known for the weight-loss drug Wegovy and diabetes treatment Ozempic, will explore how
[4]
Novo partners with Anthropic to speed up drug development with Claude
The Danish drugmaker will initially test Anthropic models and Claude Science in its research and development workflows, and address scientific problems where their joint capabilities can have the greatest impact, they said. Novo Nordisk has partnered with Anthropic to use the AI giant's Claude
[5]
Novo Nordisk, Anthropic Team Up For AI Drug Research - Novo Nordisk (NYSE:NVO)
Novo Nordisk A/S (NYSE:NVO) announced a collaboration with Anthropic that it says will help accelerate the development of new medicines. The companies will jointly address key drug discovery challenges identified by scientists at Novo, develop targeted solutions for specific scientific challenges
[6]
Novo partners with Anthropic to speed up drug development with Claude
Novo Nordisk has partnered with Anthropic to use the AI giant's Claude models to speed up discovery and development of new medicines, the companies said on Wednesday. Here are more details: The Danish drugmaker will initially test Anthropic models and Claude Science in its research and
[7]
Novo Partners With Anthropic to Speed Up Drug Discovery Using Claude
Novo Nordisk and Anthropic are teaming up to deploy the Claude artificial-intelligence model with the aim of accelerating the development of new medicines, the latest partnership between the Wegovy maker and an AI lab. The companies said Wednesday that their collaboration aims to address key
[8]
Novo Nordisk launches collaboration with Anthropic
Danish drugmaker Novo Nordisk is launching a collaboration with AI company Anthropic to speed the development of new medicines and strengthen AI-driven software development. That is according to a press release. As a first step, Novo Nordisk will test Anthropic's Claude Science in selected
Share
Copy Link
Novo Nordisk announced a collaboration with Anthropic to use Claude AI models for drug discovery and development. The pharmaceutical giant already uses Claude to cut patient documentation time from months to minutes and now aims to compress decades of biological breakthroughs into years through AI-driven research and development.
Novo Nordisk and Anthropic Join Forces for AI Drug Discovery
Novo Nordisk has announced a strategic partnership with Anthropic to deploy Claude AI models across its research and development operations, marking another significant move in the pharmaceutical giant's ambition to become the world's most AI-driven healthcare company
1
2
. The Danish company behind Ozempic and Wegovy will use Anthropic's Claude Science model to accelerate drug discovery and compress the timeline from research to marketed product3
.
Source: ET
"Joining forces with Anthropic will supercharge our R&D organisation and help us on our mission to bring new, transformative health solutions to people living with chronic diseases," said Mike Doustdar, president and CEO of Novo Nordisk
1
. Dario Amodei, co-founder and CEO of Anthropic, emphasized that AI's increasing capability brings the potential to compress a century's worth of biological and medical breakthroughs into a decade2
.Claude AI Models Transform Research and Development Workflows
Novo Nordisk will initially test Claude Science for specific research and development workflows, focusing on scientific problems where the combined capabilities of both companies are expected to have the greatest impact
4
. The pharmaceutical giant already uses Claude to automate clinical trial reporting, reducing the time needed to produce patient documentation from months to minutes3
.
Source: Benzinga
Beyond increasing productivity, AI tools can offer completely new scientific opportunities and aid reasoning and understanding of human biology and drug mechanics, according to Doustdar
4
. The collaboration will help researchers better analyze data and navigate complex questions about biological systems, potentially shortening research timelines and improving outcomes3
.AI-Driven Healthcare Strategy Expands Across the Biopharma Sector
This partnership represents another step in Novo Nordisk's broader strategy to integrate AI across its operations, building on current AI initiatives with other technology partners
3
. The company will also use Anthropic's frontier models to strengthen AI-driven software development, which is essential for scaling AI across the organization4
.The arrangement incorporates data governance protocols and human oversight requirements to ensure AI use remains consistent with the company's compliance standards
1
. This approach reflects growing attention to responsible AI deployment in the biopharma sector. Novo previously partnered with OpenAI in April to use GPT-Rosalind for analyzing complex datasets and identifying potential drugs2
.Related Stories
Industry-Wide Push to Speed Up Drug Development Through AI
The deal underscores a broader push by drugmakers to integrate AI across research and development to accelerate drug discovery
2
. Anthropic announced a collaboration with Bristol Myers Squibb in May 2026 to deploy Claude across research, clinical development, manufacturing, and commercial functions2
. Other pharmaceutical companies including Eli Lilly, Merck, and Takeda have also struck significant AI-related agreements3
.
Source: Inc.
In June, Owkin and Sanofi expanded their partnership through a multi-year collaboration focused on developing next-generation AI-powered biopharma agents, including a five-year license for Owkin's AI Scientist platform
5
. In 2024, the Novo Nordisk Foundation partnered with Nvidia and the Export and Investment Fund of Denmark to establish the Danish Centre for AI Innovation, which operates Gefion, Denmark's first AI-ready supercomputer2
. By giving leading researchers access to safe, capable, and trusted frontier models, companies aim to discover medicines and treatments that significantly improve human life while maintaining workflow optimization and scientific reasoning capabilities4
.References
Summarized by
Navi
Related Stories
Novo Nordisk partners with OpenAI to accelerate drug discovery and obesity treatment development
14 Apr 2026•Technology
Anthropic launches Claude Science workbench and plans to develop drugs for rare diseases
30 Jun 2026•Technology
Anthropic Launches Claude for Life Sciences, Aiming to Revolutionize Scientific Research
20 Oct 2025•Science and Research
Recent Highlights
1
AI Hallucination Nearly Sparked US Military Confrontation With Chinese Ship in Middle East
Technology
2
Google Gemini Hacked Three Real Companies During Cybersecurity Testing, Raising AI Safety Concerns
Technology
3
OpenAI Claims AI Breakthrough on Navier-Stokes Problem, Sparking Math Community Crisis
Science and Research
Recent Highlights
Today's Top Stories
Don’t drown in AI news. We cut through the noise - filtering, ranking and summarizing the most important AI news, breakthroughs and research daily. Follow topics that matter to you and stay ahead.
